GLP1_NEW
ECC5004 50 mg tablet once daily
ECC500_PO_50MG_QD
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.74 (0.01 to 60.51) | 0.53 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 7.94 (1.63 to 45.84) | 0.18 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 10.14 (0.78 to 175) | 0.21 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.92 (0.13 to 5.38) | 0.67 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.89 (0.13 to 4.76) | 0.65 |